Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan

October 18, 2010 By Bio-Medicine.Org

PARIS and KYOTO, Japan, Oct. 18 /PRNewswire/ — Cellectis
(Alternext: ALCLS), the French genome engineering specialist, and
iPS Academia Japan Inc. (Kyoto, Japan) announced today that they
have signed two separate non-exclusive agreements granting
Cellectis worldwide access to the induced Pluripotent Stem (iPS)
cells patent portfolio arising from the work of Professor Shinya
Yamanaka, MD, Ph.D., Center for iPS Cell Research and Application
(CiRA) at the University of Kyoto, Japan.

The agreements allow Cellectis and its affiliates to research,
develop and commercialize both research tools (covered by one
agreement) and human therapeutics or prophylactics (covered by the
second agreement) derived from iPS cells, in a certain range of
differentiated cell lineages. Cellectis is the first company
worldwide to be licensed by iPS Academia Japan under this iPS cell
patent portfolio for human therapeutics and prophylactics. In the
research tool field, this is the first agreement with French
company following agreements with US and German companies.
 

In 2006, Prof. Shinya Yamanaka and his colleagues first
described the process by which iPS cells – somatic cells that have
been reprogrammed to behave like embryonic stem cells – can
differentiate into any other cell type. This breakthrough research
has provided the scientific community with the tools to generate an
endless source of stem cells. Importantly, iPS cells are not
associated with the ethical issues attendant to embryonic
cells.

Cellectis’ unique genome engineering expertise and technology
allows precise and reproducible targeted modifications in the
genome of living cells and organisms. The iPS cell technologies
will be used by Cellectis, and Ectycell, its subsidiary focused on
industrial applications of iPS cells, to engineer these cells and
derive consistent lines of robust products both as tools and as
therapeutics.

“These agreements provide Cellectis with a powerful
combin

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech